BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
BioCentury | Mar 10, 2017
Targets & Mechanisms

Poly drugs for polycomb

...the three core enzyme-related proteins, EED , EZH2 and SUZ12 ; RBBP4 (not shown); and JARID2...
...methylation activity. EED- Embryonic ectoderm development; EZH2 - Enhancer of zeste homolog 2; JARID2 - Jumonji and AT-Rich interaction domain containing 2...
BioCentury | Jun 23, 2016
Distillery Techniques

Techniques: Structural analyses of polycomb repressive complex 2 (PRC2) bound to an inhibitor and a mutant histone H3 substrate

...disrupt this interaction. Analysis of co-crystals of the three PRC2 subunits, two PRC2 cofactors - jumonji and AT-Rich interaction domain containing 2 (JARID2)...
BioCentury | Feb 18, 2016
Distillery Techniques

Techniques: Lysine demethylase 5D (KDM5D; JARID1D) as a survival marker in prostate cancer

Biomarkers TECHNOLOGY: Gene profiling Tumor levels of KDM5D could help predict survival in prostate cancer. In 39 prostate cancer patients, low levels of KDM5D in primary tumors were associated with poor survival. Next steps could...
BioCentury | Aug 15, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Jumonji/ARID domain containing protein 1C (KDM5C; JARID1C) Studies in patient samples, cultured cells and flies suggest inhibiting JARID1C could help to treat...
BioCentury | Jul 25, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Mitochondrial oxidative phosphorylation Cell culture and mouse studies suggest inhibiting oxidative phosphorylation could help treat drug-resistant melanoma. In cultured, drug-resistant melanoma cells that highly...
BioCentury | Jun 9, 2008
Emerging Company Profile

Constellation: More epigenetic stars

Researchers have been working in the field of epigenetics for a long time, but so far few targets have been identified. And only two classes of targets - histone deacetylases and DNA methyltransferases - have yielded approved...
Items per page:
1 - 7 of 7